Tango Therapeutics, Inc. Shares Outstanding (Cover Page)
Tango Therapeutics, Inc. (TNGX) had Shares Outstanding (Cover Page) of 168.61 million shares as of 2026-08-04, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Cover Page
dei:EntityCommonStockSharesOutstanding · last filed 2026-08-11
- 2026-08-04: Entity Common Stock, Shares Outstanding 168.61M shares.
- 2026-05-06: Entity Common Stock, Shares Outstanding 144.65M shares.
- 2026-02-26: Entity Common Stock, Shares Outstanding 142.69M shares.
- 2025-10-28: Entity Common Stock, Shares Outstanding 134.59M shares.
| Period end | Entity Common Stock, Shares Outstanding |
|---|---|
| 2026-08-04 | 168.61M shares 10-Q · filed 2026-08-11 |
| 2026-05-06 | 144.65M shares 10-Q · filed 2026-05-13 |
| 2026-02-26 | 142.69M shares 10-K · filed 2026-03-05 |
| 2025-10-28 | 134.59M shares 10-Q · filed 2025-11-04 |
| 2025-07-29 | 111.26M shares 10-Q · filed 2025-08-05 |
| 2025-05-05 | 108.39M shares 10-Q · filed 2025-05-12 |
| 2025-02-19 | 108.11M shares 10-K · filed 2025-02-27 |
| 2024-11-01 | 107.42M shares 10-Q · filed 2024-11-06 |
| 2024-08-01 | 107.14M shares 10-Q · filed 2024-08-07 |
| 2024-03-12 | 106.72M shares 10-K · filed 2024-03-18 |
| 2023-08-01 | 88.47M shares 10-Q · filed 2023-08-07 |
| 2023-05-02 | 88.41M shares 10-Q · filed 2023-05-09 |
| 2023-03-20 | 88.20M shares 10-K · filed 2023-03-27 |
| 2022-11-02 | 88.18M shares 10-Q · filed 2022-11-10 |
| 2022-08-02 | 88.04M shares 10-Q · filed 2022-08-10 |
| 2022-05-02 | 87.90M shares 10-Q · filed 2022-05-11 |
| 2022-03-21 | 87.71M shares 10-K · filed 2022-03-28 |
| 2021-11-05 | 87.55M shares 10-Q · filed 2021-11-09 |
| 2021-08-06 | 21.38M shares 10-Q · filed 2021-08-09 |
| 2021-05-14 | 21.38M shares 10-Q · filed 2021-05-14 |
| 2021-03-31 | 21.38M shares 10-K · filed 2021-03-31 |
| 2020-11-13 | 21.38M shares 10-Q · filed 2020-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |